In the total IBD cohort, both mucosal eosinophil counts (n = 24) and serum eotaxin-1 levels (n = 64) significantly discriminated between patients who responded and did not respond to vedolizumab induction therapy, as represented by areas under the ROC curve (AUCs) of 0.90 (95% CI: 0.75–1.00, p < 0.01) and 0.72 (95% CI: 0.59–0.85, p < 0.01), respectively (Table 4 and Figure 3). The gene discussed is CCL11; the disease is inflammatory bowel disease.